RinuaGene Biotechnology develops mRNA-based therapeutic vaccines and immunotherapy drugs using a proprietary AI algorithm and high-throughput screening platform to identify and design drug candidates. The company addresses the need for effective treatments for HPV-related tumors and precancerous lesions, exemplified by its FDA-approved RG002 vaccine targeting cervical intraepithelial neoplasia.
Funding
Funding not disclosed
Founders
Product
Problem
Human papillomavirus (HPV)-related tumors and precancerous lesions, such as cervical intraepithelial neoplasia, lack effective treatments, creating a need for innovative therapeutic interventions. Current treatment options may have limited efficacy or undesirable side effects.
Solution
RinuaGene Biotechnology develops mRNA-based therapeutic vaccines and immunotherapy drugs designed to target HPV-related tumors and precancerous lesions. The company utilizes a proprietary AI algorithm and high-throughput screening platform to identify and design drug candidates. Their lead candidate, RG002, is an mRNA therapeutic vaccine targeting cervical intraepithelial neoplasia (CIN2/3) related to HPV types 16 and 18. The vaccine is formulated with lipid nanoparticles (LNP) for efficient delivery of the mRNA payload.
Target Audience
The primary target audience includes patients with HPV type 16 and/or 18-related cervical intraepithelial neoplasia (CIN2/3) and healthcare providers specializing in gynecology and oncology.
Features
- Proprietary AI algorithm for identifying and designing mRNA drug candidates
- High-throughput screening platform for rapid evaluation of vaccine efficacy
- RG002: mRNA-LNP therapeutic vaccine specifically targeting HPV type 16 and/or 18-related cervical intraepithelial neoplasia (CIN2/3)